BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate

The investigational new drug (IND) application was submitted by Telix's partner in the Greater China region, Grand Pharmaceutical Group Limited (...

April 11, 2023 | News

Evopoint, MSD Partner for Clinical Trial of XNW5004 with KEYTRUDA in Solid Tumors.

XNW5004 is a rationally designed, highly selective and potent EZH2 inhibitor with potentially best-in-class efficacy and safety profile demonstrated in a P...

April 10, 2023 | News

China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released

Developed with site specific conjugate technology, 9MW2821 is China's first, global second Nectin-4 targeted ADC approved for clinical study. The...

April 08, 2023 | News

First patient dosed in China Phase III trial for COPD, announces Nuance Pharma

Ensifentrine is a first-in-class, selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4") combining bronchodilator and non-s...

April 07, 2023 | News

Singapore HSA Accepts Everest Medicines' Nefecon Application for IgA Nephropathy Treatment

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commerc...

April 06, 2023 | News

WuXi STA Adds New Peptide Manufacturing Capacity and Large-Scale Continuous Purification System

WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announces that it has added two 2,000 L reactors and a lar...

April 06, 2023 | News

Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis

"BSI-045B is a next generation anti-TSLP mAb with high affinity and bioactivity that has the potential to offer greater therapeutic potential for patients ...

April 05, 2023 | News

Mabwell's Biosimilar Denosumab solution approved by NMPA for osteoporosis treatment

Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection (...

April 04, 2023 | News

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

LNK01003 is an oral small molecule JAK inhibitor with intestine-restricted properties developed by the company for the treatment of ulcerative colitis and ...

April 04, 2023 | News

Genscript Biotech Reports 2022 Annual Results

Revenue of the Group for the year ended December 31, 2022 was approximately US$625.7 million, representing an increase of 27.7% as compare...

March 31, 2023 | Company results

Boao Forum for Asia Enters the Healthcare Sector

Boao, the seaside resort and convention destination on the South China Sea coast, has again caught the attention of the entire world. Boao Lecheng Internat...

March 31, 2023 | News

Ablaze Pharmaceuticals to Develop GPC3 Targeted Therapy for Liver Cancer in China

The proprietary GPC3 targeting peptide is being licensed from RayzeBio pursuant to an existing license agreement. Upon in-license of product candidates by ...

March 31, 2023 | News

ImmVira's MVR-C5252 for Malignant Glioma Approved for Clinical Trial in China

In July 2022, the Company entered into a cooperative agreement with China Resource Biopharma ("CRBio") to jointly develop MVR-C5252 in the Greate...

March 30, 2023 | Regulatory

Scivita Medical enters into Strategic Agreement with Boston Scientific in China

Under Scivita Medical's comprehensive product lineup of reusable endoscopes, single-use videoscopes and related systems and equipment, this cooperation fur...

March 30, 2023 | News

Stay Connected